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Abstract
CD24 is a small, heavily glycosylated, GPI-linked membrane protein, whose expression
has been associated with the tumorigenesis and progression of several types of cancer.
Here, we studied the expression of CD24 in tumors of MMTV-PyMT, Apc1572/T+ and
TRAMP genetic mouse models that spontaneously develop mammary or prostate carci-
noma, respectively. We found that CD24 is expressed during tumor development in all
three models. In MMTV-PyMT and Apc1572T/+ breast tumors, CD24 was strongly but hetero-
geneously expressed during early tumorigenesis, but decreased in more advanced stages,
and accordingly was increased in poorly differentiated lesions compared with well differenti-
ated lesions. In prostate tumors developing in TRAMP mice, CD24 expression was strong
within hyperplastic lesions in comparison with non-hyperplastic regions, and heteroge-
neous CD24 expression was maintained in advanced prostate carcinomas. To investigate
whether CD24 plays a functional role in tumorigenesis in these models, we crossed CD24
deficient mice with MMTV-PyMT, Apc1572T/+ and TRAMPmice, and assessed the influence
of CD24 deficiency on tumor onset and tumor burden. We found that mice negative or posi-
tive for CD24 did not significantly differ in terms of tumor initiation and burden in the genetic
tumor models tested, with the exception of Apc1572T/+ mice, in which lack of CD24 reduced
the mammary tumor burden slightly but significantly. Together, our data suggest that while
CD24 is distinctively expressed during the early development of murine mammary and
prostate tumors, it is not essential for the formation of tumors developing in MMTV-PyMT,
Apc1572T/+ and TRAMP mice.
Introduction
CD24, also known as heat stable antigen (HSA) or CD24a in the mouse, is a small GPI-linked
membrane glycoprotein. Consisting of only around 30 amino acids [1–3], CD24 is heavily
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N- and O-glycosylated, and has a molecular weight of 30 to 70 kDa, depending on the state of
glycosylation [4].
CD24 is expressed by cells of the hematopoietic and immune systems [5–7], in the develop-
ing brain, kidney, prostate and mammary gland [8–11], and in gastrointestinal cells such as
Paneth cells and parietal cells [12,13]. Functionally it has been implicated in hematopoiesis and
immune cell function [14,15], neurite outgrowth [16,17], clonal expansion of T-cells [18] and
mammary gland development [11]. Consistently, CD24 deficient mice exhibit quantitative and
qualitative alterations in several types of immune cell [19–21], increased neurogenesis [22],
transiently enhanced branching morphogenesis in mammary glands [11], and modified gastro-
intestinal pathophysiology [13,23].
A broad literature associates CD24 expression with the development and progression of
human tumors. Upregulated CD24 expression has been reported for many types of human
cancer [24], and its expression correlates significantly with different clinicopathologic proper-
ties [25–30]. Furthermore, CD24 expression has been shown to have prognostic relevance for
the survival of patients suffering from a variety of cancer types, including breast and prostate
[28–32]. Patient survival is closely linked to metastasis [33]. Accordingly, we and others have
shown that CD24 can promote metastasis in a number of ways [24,34–39].
CD24 expression has been shown to be upregulated during tumorigenesis in gastric, colon
and breast cancer patients [27,40], suggesting that besides its role in tumor progression and
metastasis, CD24 may also play a role in early tumor development. To determine if this is the
case, we examined here the expression of CD24 during autochthonous tumorigenesis in the
mouse mammary tumor virus-polyoma middle T (MMTV-PyMT) and adenomatous polypo-
sis coli (Apc1572T/+) genetic mouse models of breast cancer, as well as in the transgenic adeno-
carcinoma of mouse prostate (TRAMP) cancer model, and determined the effect of CD24
deficiency on tumorigenesis in these models. MMTV-PyMT mice express the mammary
tumor virus-polyoma middle T (PyMT) oncoprotein under the control of mouse mammary
tumor virus LTR (MMTV LTR) [41]. Thus, PyMT expression is restricted to mammary epithe-
lium, and induces the malignant transition from benign lesions to invasive carcinoma in dis-
tinct stages (hyperplasia, adenoma/mammary intraepithelial neoplasia, early carcinoma, late
carcinoma) with subsequent metastasis, thereby recapitulating the development of luminal-like
human breast cancer [42,43]. Apc1572T/+ mice carry a mutated Apc gene encoding for a protein
truncated at position 1572, resulting in a predisposition to the development of multifocal
basal-like mammary tumors that resemble human metaplastic carcinoma [44]. TRAMP mice
develop prostate tumors that phenocopy the pathogenesis of the human disease due to trans-
genic expression of the SV40 large T antigen under control of the probasin promoter [45,46].
The studies we present here suggest that although CD24 is expressed during murine mammary
and prostate tumorigenesis, its genetic ablation does not affect tumor formation and growth in
either model.
Materials and Methods
Immunohistochemistry
Mammary glands, prostates and seminal vesicles were embedded in cryosectioning medium,
and 8–10 μm sections were prepared. The sections were then fixed in cold acetone, blocked
with 10% goat serum/1% rabbit serum in PBS, and a biotin blocking kit (DAKO, Hamburg,
Germany), and incubated with primary antibodies directed against CD24 (Becton Dickinson,
Heidelberg, Germany) over night at 4°C. Binding of the primary antibody was visualised using
biotin-coupled secondary antibodies and an alkaline-phosphatase-complex (DAKO). Fuchsin
was used as a chromogenic substrate. The sections were counterstained with hematoxylin, and
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analysed using an Axioskop microscope (Zeiss, Jena, Germany) equipped with an Axiocam
camera (Zeiss), and Axiovision software (Zeiss). Histopathological analysis was performed,
and the intensity of the CD24 staining was evaluated using the following scoring system:—no
staining; + moderate staining; ++ strong staining. To test the null hypothesis "staining intensity
is independent of histopathologic appearance", two-sided Fisher´s exact tests were performed.
Experimental mice and genotyping
Mice were maintained on a C57BL/6 background and genotyped as follows. For Apc1572T/+
mice, primers APC-C2, APC-A3 and APC-pN3 were applied in a single PCR reaction that
amplified a 180 bp fragment for the wild type Apc gene, and an additional 250 bp fragment in
the case of heterozygous mutant mice. Transgenic MMTV-PyMT offspring were identified
using PymT3p and PymT4m primers to amplify a 160 bp fragment of the PyMT transgene,
and Plg-in2-3' and Plg-ex2-5' primers to amplify a 268 bp fragment of the plasminogen precur-
sor gene as an internal control. B6,Tg(TRAMP)8247Ng(T/+) mice were genotyped with Tag
rev and PB1 for primers to amplify the transgene (600 bp fragment), while amplification of a
500 bp casein fragment with mCasein forward and mCasein reverse primers served as an inter-
nal control. The presence of knockout or wild-type alleles of the CD24 gene was assessed by
using three primers (wt fw, KO rev and 5’neo rev) in a single reaction. The amplified products
were 300 bp for the wild-type allele and 550 bp for the knockout allele.
Primer sequences were as follows:
APC-C2 (5’-GGAAAAGTTTATAGGTGTCCCTTCT-3’)
APC-A3: (5’-CTAGCCCAGACTGCTTCAAAAT-3’)
APC-pN3: (5’-GCCAGCTCATTCCTCCACTC-3’)
PymT3p: (5’-CGGCGGAGCGAGGAACTGAGGAGAG-3’)
PymT4m: (5’-TCAGAAGACTCGGCAGTCTTAGGCG-3’)
Plg-in2-3': (5’-TGTGGGCTCTAAAGATGGAACTCC-3’)
Plg-ex2-5': (5’-GACAAGGGGACTCGCTGGATGGCTA-3’)
mCasein forward: 5’-GATGTGCTCCAGGCTAAAGTT-3’
mCasein reverse: 5’-AGAAACGGAATGTTGTGGAGT-3’
Tag rev: 5’-CTCCTTTCAAGACCTAGAAGGTCCA-3’
PB1for: 5’-CCGGTCGACCGGAAGCTTCCACAAGTGCATTTA-3’
mCasein forward: 5’-GATGTGCTCCAGGCTAAAGTT-3’
mCasein reverse: 5’-AGAAACGGAATGTTGTGGAGT-3’
wt fw: 5’-AGCGGACATGGGCAGAGCGATGGTGG-3’
KO rev: 5’-GTGGTTCGCAGGGAGCGCGAAGACCTC-3’
5’neo rev: 5’-TGACAGCCGGAACACGGCGGCATCAGA-3’
Animal experiments
In experiments where MMTV-PyMT, Apc1572T/+, and TRAMP mice were crossed with CD24-/-
mice [19], animals heterozygous for the tumor-initiating transgene/mutation and either
CD24-/- or CD24+/+ were used. To assess the effect of CD24 deficiency on tumor development
in MMTV-PyMT, Apc1572T/+ models, female mice that were either CD24-/- or CD24+/+ were
palpated weekly to establish the age at which mammary tumors could first be detected. Follow-
ing tumor detection, tumors were measured twice a week. When one tumor reached 1 cm in
diameter in one dimension, animals were sacrificed, tumors and mammary tissue were
removed in total and weighed. Male TRAMP mice that were either CD24-/- or CD24+/+ were
sacrificed at the fixed time point of 6 months of age. Prostate and seminal vesicles were then
excised and weighed.
CD24 and Tumorigenesis
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All animal experiments were performed according to German legal requirements. In accor-
dance with the German law that was active at the time when the experiments were performed, an
extra approval by the local authorities was not necessary, as we used tumor-prone genetic animal
models that were not subjected to any treatment or other intervention. Permission to breed,
house and sacrifice animals (§11) was granted to the animal facility of the Institute of Toxicology
and Genetics, Karlsruhe Institute of Technology, by the Regierungspräsidium Karlsruhe (AZ35-
9185.64). The animals were sacrificed by cervical dislocation, as requested by the German animal
work guidelines for mice. All researchers (NC (zoologist; registration date: 02.09.2009) AN
(AZ35-9185.83_09.07.2008) JPS (AZ35-9185.83_20.05.1998) WT (zoologist; registration date:
15.05.2008)) and animal facility members (Selma Huber (AZ35-9185.83_12.01.2007), Manuela
Sauer (AZ35-9185.83_28.01.2010)) that were involved in animal work for this study have been
registered or authorized by the Regierungspräsidium Karlsruhe (§9). According to the German
legal requirements zoologists (NC,WT) need no extra permission to kill animals, they need only
to be registered at the Regierungspräsidium, which was done at the indicated dates.
Results
CD24 is expressed in MMTV-PyMT and Apc1572T/+ mammary tumors,
and CD24 expression correlates with differentiation grade of the lesions
The normal expression pattern of CD24 in the non-transformed mammary gland has been
documented [11], and the stages of mammary tumorigenesis in the MMTV-PyMT model [42]
and Apc1572T/+ model [44] have been previously described. To assess the expression pattern of
CD24 in these two breast cancer models, female animals of different ages were sacrificed, and
their mammary glands analysed by staining sections immunohistochemically for CD24.
In the MMTV-PyMT model we observed that hyperplastic pre-neoplastic lesions and small
adenomas stained strongly for CD24 (Fig 1A), reflecting expression in the normal mammary
epithelium, where it is predominantly present in the luminal epithelium and only weakly
expressed in basal myoepithelial cells [11]. However, heterogeneity was observed in the distri-
bution of the stained cells, with some hyperplastic lesions being stained strongly, whereas oth-
ers were negative (Fig 1A). Furthermore, different degrees of staining or areas of CD24
positivity were often present within one and the same neoplastic lesion, with some parts being
stained whereas other parts were not (Fig 1C). The expression levels of CD24 were increased in
poorly differentiated versus well-differentiated lesions and correlated with tumor grade in a sta-
tistically significant manner (Fig 1D; S1 Table). Accordingly, as tumors progressed and
increased in size, staining intensity generally decreased, and more advanced tumors showed
either weak and diffuse staining (Fig 1E) or were completely negative for CD24 (Fig 1F).
Immunohistochemical analysis of Apc1572T/+ tumors reflected the squamous metaplasia
morphology described previously [44]. CD24 staining was prominent and intense in the epi-
thelial layers surrounding the fibrillar deposits found in the squamous metaplasia (Fig 2A and
2C), while staining was weaker in adenocarcinomas (Fig 2D). We found a strong and statisti-
cally significant correlation between differentiation grade (poorly and well differentiated,
respectively) and staining intensity (Fig 2E; S2 Table).
Lack of CD24 does not affect tumorigenesis in MMTV-PyMT and
Apc1572T/+ breast cancer models significantly, but reduces mammary
tumor burden in Apc1572T/+ mice
To assess the effect of CD24 deficiency on mammary tumor development and growth, MMTV-
PyMT and Apc1572T/+ mice that were either CD24+/+ or CD24-/- were palpated weekly to
CD24 and Tumorigenesis
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Fig 1. CD24 is expressed during MMTV-PyMTmammary tumorigenesis. To determine the expression of CD24 during tumorigenesis, female
MMTV-PyMT mice were sacrificed at a variety of ages, and their mammary glands were cut into sections and stained with antibodies specific for CD24. After
counterstaining with hematoxylin, the sections of 12 animals were photographed and analysed. Representative sections are shown. Scale bars indicate
100 μm. (A) Hyperplastic preneoplastic lesions and small adenomas that are either stained strongly or negative for CD24. (B) Isotype control stained serial
section corresponding to A. (C) Different degrees of CD24 staining within one and the same neoplastic lesion. (D) A histopathologic analysis was performed
and the intensity of the CD24 staining was evaluated. Score:—no staining; + moderate staining; ++ strong staining. A two-sided Fisher´s exact test was
performed to test the null hypothesis "staining intensity is independent of histopathologic appearance". The null hypothesis was rejected based on a
calculated p-value of 0.00035 (3x3 contingency table). Scoring was categorized into CD24 negative ("-") or CD24 positive ("+" or "++"), and two-sided Fisher
´s exact tests and 2x2 contingency tables were used to perform pairwise comparisons of (i) "invasive well differentiated" vs. "invasive poorly differentiated"
(p = 0.21), (ii) "preinvasive" vs. "invasive well differentiated" (p = 0.45) and (iii) "preinvasive" vs. "invasive poorly differentiated" (p = 0.015). (E) More
advanced tumor showing weak and diffuse staining. F:More advanced tumor negative for CD24.
doi:10.1371/journal.pone.0151468.g001
CD24 and Tumorigenesis
PLOS ONE | DOI:10.1371/journal.pone.0151468 March 15, 2016 5 / 17
establish the time at which mammary tumors could first be detected after tumor initiation.
Although tumors are already initiated once they become palpable, this strategy is a well-estab-
lished method to define tumor onset in living mice, and serves as a surrogate measure of
tumor initiation. All animals developed tumors, regardless of presence or absence of CD24. Fol-
lowing tumor detection, tumors were measured twice a week. In many cases, multiple tumors
Fig 2. CD24 is expressed in mammary tumors during Apc1572/T+ tumorigenesis. To determine the expression of CD24 during tumorigenesis, female
Apc1572/T+mice were sacrificed at a variety of ages, and their mammary glands were cut into sections and stained with antibodies specific for CD24. After
counterstaining with hematoxylin, the sections of 14 animals were photographed and analysed. Representative sections are shown. Scale bars indicate
100 μm. (A) Isotype control stained serial section corresponding to (B). (B), (C) Epithelial layers surrounding the fibrillar deposits found in squamous
metaplasia staining strongly for CD24. (D) Adenocarcinoma staining weakly for CD24. (E) A histopathologic analysis was performed and the intensity of the
CD24 staining was evaluated. Score:—no staining; + moderate staining; ++ strong staining. A two-sided Fisher´s exact test was performed to test the null
hypothesis "staining intensity is independent of histopathologic appearance". The null hypothesis was rejected based on a calculated p-value of 0.0000002
(2x2 contingency table).
doi:10.1371/journal.pone.0151468.g002
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developed in the same animal. Animals were sacrificed when one tumor reached 1 cm in diame-
ter in one dimension. Tumors and mammary tissue were then removed in total and weighed.
CD24 deficiency had no significant effect on either the age at which tumors were first
detected (Fig 3A and 3B), nor on the age at which the animals were sacrificed (Fig 3C and 3D).
The effect of CD24 deficiency on the tumor burden was assessed by quantifying the mass of the
tumor-bearing mammary glands. Tumor mass was statistically significantly different (p<0.05)
between the CD24+/+ and CD24-/- groups in Apc1572T/+ mice, although the difference was mar-
ginal (Fig 3F), whereas no effect could be observed in MMTV-PyMT animals. To exclude pos-
sible morphological differences between tumors derived from CD24+/+ or CD24-/- animals, we
analysed hematoxylin-stained sections of MMTV-PyMT and Apc1572T/+ tumors, but found no
difference in the histological appearance of the tumors (Fig 3G–3I). Together, these data show
that while CD24 is expressed in both models during tumor development, CD24 deficiency had
no significant effect on the initiation of tumors and subsequently reduced tumor burden in a
statistically significant manner only in Apc1572T/+ mice, albeit marginally.
CD24 is expressed in the normal murine prostate, and during TRAMP
prostate tumorigenesis
To analyse CD24 expression during TRAMP prostate tumorigenesis, we immunostained pros-
tate sections from mice of different ages for CD24. Hyperplastic lesions or PIN (prostate intrae-
pithelial neoplasia) were observed starting from 12 weeks of age. In the normal prostate of age-
matched non-transgenic C57BL/6 mice, prominent CD24 staining was found on the lining of
the luminal layer of dorsolateral prostatic tubules (Fig 4A). However, in hyperplastic areas in
TRAMP prostates, CD24 staining was stronger compared with adjacent non-hyperplastic areas
(Fig 4B). CD24 staining in hyperplastic TRAMP lesions was generally widespread but hetero-
geneous with regard to distribution and intensity of the staining within a given tissue section
(Fig 4B). Indeed, CD24-negative PINs were observed in areas of positively-stained lesions even
within the same prostatic duct. CD24 staining was homogenous and strong in small prostate
carcinomas (Fig 4C), although differences in intensity and distribution were apparent. Larger
tumors were either CD24 positive (Fig 4D) or negative (Fig 4E). In the CD24-positive tumors,
strong staining was found mainly at the periphery, with staining towards the necrotic centre
being only weak or even absent. Although CD24 staining was heterogeneous, significantly
fewer invasive well-differentiated tumors expressed CD24 compared to other tumor stages (Fig
4F; S3 Table).
CD24 deficiency does not significantly influence tumorigenesis in
TRAMPmice
Due to the internal development of prostate tumors, it was not possible to determine accurately
when tumors first began to develop in the TRAMP model. To assess whether CD24 deficiency
affects tumor development in this model, animals were therefore sacrificed at the fixed time
point of 6 months of age. In addition to prostate tumors, TRAMPmice on the C57BL/6 back-
ground develop epithelial-stromal seminal vesicle tumors that reach an incidence of 100% at 6
months [47]. Both prostate and seminal vesicles were therefore excised and weighed separately
when the animals were sacrificed.
Although there was a trend towards slightly reduced tumor burden in CD24-deficient ani-
mals, no significant difference in the burden of prostate or seminal vesicle tumors was observed
(Fig 5A and 5B). There was also no difference in the morphology of tumors taken from CD24-/-
or CD24+/+ mice (Fig 5C and 5D). These data show that despite frequent and prominent
CD24 and Tumorigenesis
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Fig 3. CD24 deficiency does not affect MMTV-PyMTmammary tumorigenesis, but reduces tumor burden in Apc1572/T+mice. To study the effect of
CD24 deficiency on mammary tumor initiation and growth, MMTV-PyMT and Apc1572/T+mice were crossed withCD24-/-mice. Female MMTV-PyMT and
Apc1572/T+mice eitherCD24-/- or CD24+/+ were regularly palpated to monitor the time point of tumor onset. Following onset, tumors were measured regularly
and animals were sacrificed when the tumors reached 1 cm in diameter in one dimension. Tumors and mammary tissue were then removed in total, and their
mass was determined as a measure for tumor burden. Error bars indicate SE. Significance was tested using 2-tailed un-paired t tests assuming equal
variance. Scale bars indicate 100 μm. (A) Age at which tumors were first detected in MMTV-PyMTmice; CD24+/+: n = 20;CD24-/-: n = 21. (B) Age at which
tumors were first detected in Apc1572/T+mice; CD24+/+: n = 19; CD24-/-: n = 20. (C) Age at which MMTV-PyMTmice were sacrificed;CD24+/+: n = 20;
CD24-/-: n = 21. (D) Age at which Apc1572/T+mice were sacrificed;CD24+/+: n = 19; CD24-/-: n = 21. (E) MMTV-PyMT tumor burden;CD24+/+: n = 20; CD24-/-:
n = 21. F: Apc1572/T+ tumor burden; CD24+/+: n = 19;CD24-/-: n = 20 * p<0.05. (G), (H) Representative hematoxylin stained sections of MMTV-PyMTCD24+/+
(left panels) and MMTV-PyMTCD24-/- (right panels) mammary tumors. Evaluation of the sections showed poorly differentiated mammary carcinoma in situ/
carcinoma (G3) with additional accompanying earlier stage lesions (hyperplasia, papilloma, adenoma) present in virtually all tumors. There was no difference
betweenCD24+/+ andCD24-/-MMTV-PyMTmammary tumors with the exceptions that necrotic areas were slightly less frequent in CD24-/- tumors. (I)
Representative hematoxylin stained sections of Apc1572/T+ CD24+/+ (left panel) and Apc1572/T+ CD24-/- (right panel) mammary tumors. Histopathologic
evaluation of the sections showed metaplastic carcinoma with squamous cell-like differentiation (well-differentiated; G1). There was no obvious difference
betweenCD24+/+ andCD24-/- Apc1572/T+mammary tumors.
doi:10.1371/journal.pone.0151468.g003
CD24 and Tumorigenesis
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Fig 4. CD24 is expressed in prostate tumors during TRAMP tumorigenesis.Male TRAMPmice were
sacrificed at a variety of ages, and their prostate glands were cut into sections and stained with antibodies
specific for CD24. After counterstaining with hematoxylin, the sections of 52 animals were photographed and
analysed. Representative sections are shown. Scale bars indicate 100 μm. (A) Prostate gland of a 12 week
old C57BL/6 mouse showing the linings of the luminal layer of dorsolateral tubules staining positively for
CD24. (B) Hyperplastic lesions in the prostate of a 12 week old TRAMPmouse with widespread but
inhomogenous CD24 staining being stronger in hyperplastic areas, compared with adjacent non-hyperplastic
regions. (C) Small TRAMP tumor staining homogenously and strongly for CD24. Larger TRAMP tumors were
either CD24-positive (D) or negative (E). (F) A histopathologic analysis was performed and the intensity of the
CD24 staining was evaluated. Score:—no staining; + moderate staining; ++ strong staining. A two-sided
CD24 and Tumorigenesis
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expression of CD24 in TRAMP tumors, absence of CD24 did not significantly influence tumor
burden.
Discussion
Here, we show that in MMTV-PyMT, Apc1572T/+, and TRAMP mice, CD24 is prominently but
heterogeneously expressed during early breast and prostate tumorigenesis. While CD24
expression inversely correlated with tumor grade, and thus generally decreased in progressive
mammary tumors, it remained robustly expressed in some but not all more advanced prostate
tumors. The data presented here also demonstrate that lack of CD24 did not significantly alter
tumor initiation in any of the autochthonous tumor models studied. Tumor burden was inde-
pendent of CD24 expression in MMTV-PyMT and TRAMP mice, and was reduced in
CD24-deficient Apc1572T/+ tumors in a statistically significant manner, albeit only marginally.
In the non-transformed murine breast, CD24 is predominantly expressed by luminal epi-
thelial cells [11]. Our data show that in luminal-like MMTV-PyMT and in metaplastic
Apc1572T/+ tumors that represent a model for a subtype of human triple negative basal-like
breast cancers [48], CD24 can be upregulated during early tumorigenesis (Figs 1A, 1C, 1D and
2B–2D; S1 and S2 Tables). In line with these findings, upregulation of CD24 expression has
been reported for human ductal carcinoma in situ relative to non-transformed tissue [40].
However, while we found that CD24 expression decreased with advanced tumor progression
and tumor grade both in MMTV-PyMT and in Apc1572T/+ mice (Figs 1D, 1E and 2D; S1 and S2
Tables), the expression of CD24 in late stage human invasive carcinoma of the breast is signifi-
cantly increased in comparison with non-tumor tissue [40]. Our findings suggest that differ-
ences in CD24 expression in advanced luminal breast tumors exist between human patients
and the MMTV-PyMT genetic mouse model. No data regarding CD24 expression are available
specifically for rare human metaplastic carcinomas that would allow a direct comparison with
the Apc1572T/+ model to be made. Similar to the findings here, CD24 positivity has been shown
to be associated with human triple negative basal-like tumors only in early lesions [49].
In prostates from TRAMP mice, enhanced CD24 staining intensity was observed within
hyperplastic lesions in comparison to adjacent non-hyperplastic regions (Fig 4B), suggesting
that CD24 expression can be increased during early prostate tumorigenesis. In human pros-
tates, CD24 expression was similarly found to be frequently present in atrophic glands and
intraepithelial neoplasia, and clearly upregulated in atypical epithelia, whereas it is rare in non-
neoplastic tissue and benign hyperplasias [28]. CD24 transcripts are also significantly increased
in human prostate tumors relative to benign prostate hyperplasias [50,51]. Similar to our find-
ings, pronounced intratumoral heterogeneity of CD24 expression has also been described for
human prostate carcinoma, and only a proportion of human invasive prostate carcinomas
were found to be positive for CD24 [28]. Thus, CD24 expression patterns and distribution in
TRAMP tumors resemble the situation in human prostate samples.
An important finding in this study is that lack of CD24 does not significantly affect tumor
incidence in any of the models investigated. Similar results have been reported in carcinogen-
induced urothelial tumors, where initiation of tumors in CD24-/- mice was significantly
delayed, but tumor incidence was not significantly different between wild-type and CD24-/-
Fisher´s exact test was performed to test the null hypothesis "staining intensity is independent of
histopathologic appearance". The null hypothesis was rejected based on a calculated p-value of 0,0000007
(3x4 contingency table). Scoring was categorized into CD24 negative ("-") or CD24 positive ("+" or "++"), and
two-sided Fisher´s exact tests and 2x2 contingency tables were used to perform pairwise comparisons of (i)
"invasive well differentiated" vs. "invasive poorly differentiated" (p = 0.006), (ii) "preinvasive" vs. "invasive well
differentiated" (p = 0.015) and (iii) "preinvasive" vs. "invasive poorly differentiated" (p = 0.45).
doi:10.1371/journal.pone.0151468.g004
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Fig 5. Lack of CD24 does not significantly affect TRAMP prostate and seminal vesicle tumor burden. To study the effect of CD24 deficiency on
prostate tumorigenesis, TRAMPmice were crossed withCD24-/-mice. Male TRAMPmice either -/- or +/+ for CD24were sacrificed at 6 months of age.
Prostate and seminal vesicles were then removed in total, and their mass was determined, as a measure for tumor burden. Error bars indicate SE.
Significance was tested using 2-tailed un-paired t tests assuming equal variance. Scale bars indicate 100 μm. (A) Prostate tumor burden; CD24+/+: n = 23;
CD24-/-: n = 21. (B) Seminal vesicle tumor burden;CD24+/+: n = 23;CD24-/-: n = 21. (C) Representative hematoxylin stained sections of CD24+/+ (upper
panel)CD24-/- (lower panel) neoplastic prostates. Histopathologic evaluation of the sections predominantly showed prostatic intraepithelial neoplasia (PIN)
with small lesions developing into early invasive carcinoma. There was no difference betweenCD24+/+ andCD24-/- prostate tumors. (D) Representative
hematoxylin stained sections of CD24+/+ (upper panel)CD24-/- (lower panel) neoplastic seminal vesicles. Evaluation of the sections showed dilated seminal
vesicles with small tumor areals present. There was no difference betweenCD24+/+ andCD24-/- seminal vesicle tumors.
doi:10.1371/journal.pone.0151468.g005
CD24 and Tumorigenesis
PLOS ONE | DOI:10.1371/journal.pone.0151468 March 15, 2016 11 / 17
mice 28 weeks after treatment with carcinogen [52]. Furthermore, while our study was in prep-
aration, others reported that CD24 deficiency in TRAMP mice results in delayed onset of pros-
tate tumorigenesis, but that all mice had developed prostate tumors by 5 months of age [53].
Together these observations suggest that CD24 is not essentially required for tumorigenesis in
these models.
In contrast to the results reported here, CD24 deficiency resulted in resistance to chemically
induced colorectal cancer, and tumor formation in ApcMin mice that spontaneously develop
intestinal tumors was almost completely prevented on a CD24-/- background [54]. These obser-
vations suggest that CD24 can have cell type-specific effects on tumor initiation and growth, a
notion supported by our finding that CD24 deficiency slightly but statistically significantly
reduced tumor burden in Apc1572T/+ but not MMTV-PyMT mammary carcinomas. Cell type-
specific effects of CD24 deficiency on tumor initiation and growth could conceivably be due to
cell type-specific upregulation of compensatory molecules such as the CD24 paralog CD52 in
CD24-/- mice, although we note that no such compensatory upregulation of CD52 occurs in
the mammary glands of CD24-/- mice [11]. More likely, given that MMTV-PyMT mammary
carcinogenesis is β-catenin independent [55] and that β-catenin can regulate CD24 expression
[54], it is tempting to speculate that CD24 might be functionally relevant during APC/β-cate-
nin-dependent tumorigenesis, which might explain why some tumor types appear to be more
sensitive to CD24 deficiency than others. Furthermore, as CD24 deficiency can result in
changes in immune cell subpopulations [19–21], we also cannot currently rule out a scenario
in which CD24 deficiency affects the tumor microenvironment, for example by modulating the
numbers of tumor promoting and suppressing immune cells, which could also conceivably
have tissue-specific effects.
CD24 expression correlates with poor patient survival in a variety of human tumor types
[28,29], and a functional role for CD24 in tumor progression is well established [35,37,39]. At
first sight, reduced CD24 expression in later stages of MMTV-PyMT and Apc1572T/+ tumors,
and absence of CD24 expression in a proportion of advanced TRAMP prostate tumors may
appear contradictory with this notion. However, CD24 positivity or negativity rather than
expression intensity correlated with poor survival in human prostate and breast tumor patients
[28,29]. Moreover, metastasis has been suggested to be an early event during breast tumor
development [56], and dissemination might therefore already take place when CD24 levels are
still high. Hence, our findings that CD24 expression is reduced in but not absent from late
stages of MMTV-PyMT and Apc1572T/+ tumors, and only strongly expressed in some but not
all advanced TRAMP tumors, does not exclude a role for CD24 in subsequent metastasis. The
number of metastases that developed on the C57BL/6 background in the tumor models used in
this current study were too small to detect statistically significant differences between CD24-/-
and CD24+/+ mice. Nevertheless we note that CD24 deficiency has been reported to result in
reduced metastases from urothelial tumors, but only in male mice due to androgen-dependent
effects [52].
CD24 has gained attention as a potential marker for putative cancer stem cells (CSCs) that,
according to the CSC-concept, initiate and drive solid tumor growth [48,57,58]. Both the pres-
ence and absence of CD24 has been ascribed as a marker of putative CSCs. Thus while CD24
positivity can define populations enriched for CSCs in human carcinomas of the pancreas [59]
and ovary [60], CD24 negativity enriches for putative human breast [61] and prostate [62,63]
CSCs. In breast tumors arising in MMTV-PyMT and p53-/- mice, CD24 positivity is a marker
for CSCs [64,65]. In spheriod-forming assays using tumor cells derived from Apc1572T/+ mice,
Lin-CD29+CD24+ tumor cells gave rise to significantly more spheroids than Lin-CD29+CD24-
tumor cells, suggesting that CD24-expressing cells are enriched for stemness properties [48].
Accordingly, CD24-expressing cells possess tumor initiating properties in this model [48]. If
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CD24 functionally contributes to the stemness properties of CSCs in these models, then loss of
CD24 would be expected to have pronounced effects on tumor initiation and growth. Thus
our finding that lack of CD24 does not impair tumor incidence in the MMTV-PyMT and
Apc1572T/+ models (as assessed by the age at which tumors first become palpable) could suggest
that CD24 may not have a functional role in determining the properties of CSCs in these mod-
els. Nevertheless we cannot rule out the possibility that ex vivomanipulation of the Apc1572T/+
tumor cells for the purposes of spheriod-forming and tumor initiation experiments [48] may
have changed the properties of the tumor cells, as we have previously reported in other models
[66].
In conclusion, our data demonstrate that while CD24 is distinctively but diversely expressed
during tumor development in genetic models of breast and prostate cancer, lack of CD24 did
not significantly influence tumor initiation and only partly affected tumor burden in these
models. Furthermore, CD24 deficiency in Apc1572T/+ mice slightly but statistically significantly
reduced tumor burden, whereas no such effect was observed in MMTV-PyMTmice, suggesting
that CD24 may play different roles in different types of breast cancer. Consistently, these and
other data suggest that CD24 can influence the kinetics of tumor initiation in a context-depen-
dent manner.
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